These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 11721446)

  • 1. The effects of classic antipsychotic haloperidol plus the extract of ginkgo biloba on superoxide dismutase in patients with chronic refractory schizophrenia.
    Zhou D; Zhang X; Su J; Nan Z; Cui Y; Liu J; Guan Z; Zhang P; Shen Y
    Chin Med J (Engl); 1999 Dec; 112(12):1093-6. PubMed ID: 11721446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of extract of ginkgo biloba added to haloperidol on superoxide dismutase in inpatients with chronic schizophrenia.
    Zhang XY; Zhou DF; Su JM; Zhang PY
    J Clin Psychopharmacol; 2001 Feb; 21(1):85-8. PubMed ID: 11199954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia.
    Zhang XY; Zhou DF; Zhang PY; Wu GY; Su JM; Cao LY
    J Clin Psychiatry; 2001 Nov; 62(11):878-83. PubMed ID: 11775047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of extract of ginkgo biloba addition to olanzapine on therapeutic effect and antioxidant enzyme levels in patients with schizophrenia.
    Atmaca M; Tezcan E; Kuloglu M; Ustundag B; Kirtas O
    Psychiatry Clin Neurosci; 2005 Dec; 59(6):652-6. PubMed ID: 16401239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of Ginkgo biloba extract added to haloperidol on peripheral T cell subsets in drug-free schizophrenia: a double-blind, placebo-controlled trial.
    Zhang XY; Zhou DF; Cao LY; Wu GY
    Psychopharmacology (Berl); 2006 Sep; 188(1):12-7. PubMed ID: 16906395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A placebo-controlled study of extract of ginkgo biloba added to clozapine in patients with treatment-resistant schizophrenia.
    Doruk A; Uzun O; Ozşahin A
    Int Clin Psychopharmacol; 2008 Jul; 23(4):223-7. PubMed ID: 18545061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: an open-label pilot study.
    Sivrioglu EY; Kirli S; Sipahioglu D; Gursoy B; Sarandöl E
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1493-9. PubMed ID: 17688987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in schizophrenia: a study of patients treated with haloperidol or clozapine.
    Gama CS; Salvador M; Andreazza AC; Kapczinski F; Silva Belmonte-de-Abreu P
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 May; 30(3):512-5. PubMed ID: 16426720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparative efficacy of bromocriptine, carbamazepine and cyproheptadine with neuroleptics in 24 refractory chronic schizophrenic patients].
    Llorca PM; Wolf MA; Lançon C; Bougerol T
    Encephale; 1993; 19(5):565-71. PubMed ID: 8306925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial.
    Akhondzadeh S; Safarcherati A; Amini H
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):253-9. PubMed ID: 15694232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse effects of risperidone and haloperidol treatment in schizophrenia.
    Yen YC; Lung FW; Chong MY
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar; 28(2):285-90. PubMed ID: 14751424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients.
    Raffa M; Mechri A; Othman LB; Fendri C; Gaha L; Kerkeni A
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Oct; 33(7):1178-83. PubMed ID: 19576938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxidative-antioxidative systems and their relation with serum S100 B levels in patients with schizophrenia: effects of short term antipsychotic treatment.
    Sarandol A; Kirli S; Akkaya C; Altin A; Demirci M; Sarandol E
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Aug; 31(6):1164-9. PubMed ID: 17459548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia.
    Kane JM; Lauriello J; Laska E; Di Marino M; Wolfgang CD
    J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S29-35. PubMed ID: 18334910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effects of nuclear factor kappaB and transforming growth factor beta1 in the anti-liver fibrosis process using Ginkgo biloba extract].
    Liu SQ; Yu JP; He L; Yu HG; Luo HS
    Zhonghua Gan Zang Bing Za Zhi; 2005 Dec; 13(12):903-7. PubMed ID: 16381635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Bromperidol decanoate in the residual phase of schizophrenia].
    Smeraldi E; Cocconcelli C; Canova L; Faravelli C; Marchetti FP; Mariani G; Rapisarda V
    Minerva Psichiatr; 1996 Mar; 37(1):39-44. PubMed ID: 8926856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amoxapine as an antipsychotic: comparative study versus haloperidol.
    Chaudhry IB; Husain N; Khan S; Badshah S; Deakin B; Kapur S
    J Clin Psychopharmacol; 2007 Dec; 27(6):575-81. PubMed ID: 18004123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of clinical outcome in schizophrenic patients responding to clozapine.
    Mauri MC; Volonteri LS; Dell'Osso B; Regispani F; Papa P; Baldi M; Bareggi SR
    J Clin Psychopharmacol; 2003 Dec; 23(6):660-4. PubMed ID: 14624196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma homovanillic acid differences in clinical subgroups of first episode schizophrenic patients.
    Baeza I; Castro-Fornieles J; Deulofeu R; de la Serna E; Goti J; Salvà J; Bernardo M
    Psychiatry Res; 2009 Jul; 168(2):110-8. PubMed ID: 19501918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.